nach oben

Erschienen in:

01.10.2011 | Original Article

Geographic differences in the increasing ESRD rate have disappeared in Japan

verfasst von: Tamaki Wakamatsu-Yamanaka, Michio Fukuda, Ryo Sato, Takehiro Naito, Hiroyuki Togawa, Tatsuya Tomonari, Yoko Kato, Toshiyuki Miura, Masashi Mizuno, Tadashi Ichikawa, Sota Miyagi, Yuichi Shirasawa, Akinori Ito, Atsuhiro Yoshida, Genjiro Kimura

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

We previously showed that there are marked geographic differences in the incidence of end-stage renal disease (ESRD) within Japan. In addition, the use of renin–angiotensin system inhibitors was found to be inversely correlated with the increasing ESRD rate. It was recently demonstrated that the incidence of ESRD due to diabetic nephropathy is declining in both Europe and USA. Therefore, we investigated the increasing ESRD rate and its geographic difference in Japan.

Methods

Each year, the Japanese Society for Dialysis Therapy reports the numbers of patients initiating maintenance dialysis therapy in each prefecture of Japan. We used old (1984–1991) and recent (2001–2008) data to compare the increasing ESRD rate, which was estimated from the slope of the regression line of the annual incidence corrected for population, between the two periods in 11 regions of Japan.

Results

Increasing ESRD rate almost halved, from 11.1 ± 5.6 to 5.4 ± 0.7/million per year from the old to the recent period. Deceleration of the increasing ESRD rate from the old to the recent period was correlated with the incidence in the old period across 11 regions (r = 0.81, p < 0.003); i.e., the deceleration was greater in the regions where ESRD incidence had been higher. Whereas the increasing ESRD rate was significantly different among regions in the old period, this was not the case in the recent period, resulting in uniformity throughout Japan.

Conclusions

The increasing ESRD rate is slowing in Japan, and its geographic differences, previously observed, have disappeared.

Usami T, Koyama K, Takeuchi O, Morozumi K, Kimura G. Regional variations in the incidence of end-stage renal failure in Japan. JAMA. 2000;284:2622–4.CrossRefPubMed

Usami T, Nakao N, Fukuda M, Takeuchi O, Kamiya Y, Yoshida A, et al. Maps of end-stage renal disease and amounts of angiotensin-converting enzyme inhibitors prescribed in Japan. Kidney Int. 2003;64:1445–9.CrossRefPubMed

Sorensen VR, Hansen PM, Heaf J, Feldt-Rasmussen B. Stabilized incidence of diabetic patients referred for renal replacement therapy in Denmark. Kidney Int. 2006;70:187–91.CrossRefPubMed

Incidence of end-stage renal disease among persons with diabetes—United States, 1990–2002. MMWR Morb Mortal Wkly Rep. 2005;54:1097–100.

Jap Soc Dial Ther. An overview of dialysis treatment in Japan (as of Dec. 31, 2008). J Jap Soc Dial Ther. 2010;43:1–35.CrossRef

Rothman KL, Greenland S, Lash TL (eds). Modern Epidemiology. 3rd ed. Philadelphia:Lippincott-Raven; 2008.

Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for The Collaborative Study G. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–62.CrossRefPubMed

Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.CrossRefPubMed

Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–8.CrossRefPubMed

10.

Yamagata K, Takahashi H, Suzuki S, Mase K, Hagiwara M, Shimizu Y, et al. Age distribution and yearly changes in the incidence of ESRD in Japan. Am J Kidney Dis. 2004;43:433–43.CrossRefPubMed

11.

Kato N, Usami T, Fukuda M, Motokawa M, Kamiya Y, Yoshida A, et al. Different regional dynamics of end-stage renal disease in Japan by different causes. Nephrology (Carlton). 2005;10:400–4.CrossRef

12.

Zeier M, Fehrenbach P, Geberth S, Mohring K, Waldherr R, Ritz E. Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int. 1992;42:1259–65.CrossRefPubMed

13.

Kennefick TM, Al-Nimri MA, Oyama TT, Thompson MM, Kelly FJ, Chapman JG, et al. Hypertension and renal injury in experimental polycystic kidney disease. Kidney Int. 1999;56:2181–90.CrossRefPubMed

14.

Chapman AB, Johnson AM, Gabow PA, Schrier RW. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1994;5:1349–54.PubMed

15.

Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939–45.CrossRefPubMed

16.

Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, et al. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol. 2002;13:1733–9.CrossRefPubMed

17.

Klahr S, Breyer JA, Beck GJ, Dennis VW, Hartman JA, Roth D, et al. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J Am Soc Nephrol. 1995;5:2037–47.PubMed

18.

Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2002;35:427–32.CrossRef

19.

Jafar TH, Stark PC, Schmid CH, Strandgaard S, Kamper AL, Maschio G, et al. The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int. 2005;67:265–71.CrossRefPubMed

20.

Ecder T, Edelstein CL, Fick-Brosnahan GM, Johnson AM, Chapman AB, Gabow PA, et al. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol. 2001;21:98–103.CrossRefPubMed

21.

Furumatsu Y, Nagasawa Y, Hamano T, Iwatani H, Iio K, Shoji T, et al. Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan. Nephrol Dial Transplant. 2008;23:984–90.CrossRefPubMed

22.

Usami T, Nakao N, Fukuda M, Yoshida A, Kimura G. Renoprotective action of statin estimated from mapping renal failure in Japan. Kidney Int. 2004;65:1520.CrossRefPubMed

Titel: Geographic differences in the increasing ESRD rate have disappeared in Japan
verfasst von: Tamaki Wakamatsu-Yamanaka
Michio Fukuda
Ryo Sato
Takehiro Naito
Hiroyuki Togawa
Tatsuya Tomonari
Yoko Kato
Toshiyuki Miura
Masashi Mizuno
Tadashi Ichikawa
Sota Miyagi
Yuichi Shirasawa
Akinori Ito
Atsuhiro Yoshida
Genjiro Kimura
Publikationsdatum: 01.10.2011
Verlag: Springer Japan
Erschienen in: Clinical and Experimental Nephrology / Ausgabe 5/2011
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-011-0466-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Geographic differences in the increasing ESRD rate have disappeared in Japan